Nasal High-Frequency Oscillation for Lung Carbon Dioxide Clearance in the NewbornMukerji A. · Finelli M. · Belik J.
Division of Neonatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ont., Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Noninvasive ventilation has been used increasingly in recent years to minimize the duration of endotracheal mechanical ventilation in neonates due to its association with lung injury. Nasal high-frequency oscillation (nHFO) is a relatively new noninvasive modality but evidence for its use is limited. Objective: The goal of this study was to compare the CO2 clearance efficacy of nHFO and noninvasive positive pressure ventilation (NIPPV) in a neonatal lung model. Design/Methods: A newborn mannequin with dimensions and anatomy similar to a term infant was utilized. It was connected to a commercially available neonatal mechanical ventilator using a manufacturer-provided nasal adaptor. Various modes of noninvasive ventilation were compared as CO2 clearance was measured at the oropharynx by an end-tidal CO2 analyzer following the addition of a known amount of CO2 into the lung. Measurements were obtained at two different lung compliances using nHFO and compared with nCMV and nasal continuous positive airway pressure (nCPAP) as a control. Pressures near the nasal adaptor and the larynx were simultaneously measured with in-line pressure transducers. Results: Whereas no CO2 elimination was observed under nCPAP, its clearance with nHFO was 3-fold greater as compared to NIPPV. On nHFO, CO2 clearance was inversely proportional to frequency and maximal at 6 and 8 Hz. At a lower lung compliance, CO2 clearance was significantly higher at 6 Hz as compared to 10 Hz. During nHFO set to deliver a MAP of 10.0, we documented pressures of 7.2 ± 0.3 at the nasal adaptor and only 2.3 ± 0.3 cm H2O at the larynx. Conclusions: Nasal HFO is effective and superior to NIPPV at lung CO2 elimination in a newborn mannequin model. The use of nHFO as the preferred mode of noninvasive ventilation warrants further clinical studies.
© 2012 S. Karger AG, Basel
- Donn SM, Sinha SK: Minimising ventilator induced lung injury in preterm infants. Arch Dis Child Fetal Neonatal Ed 2006;91:226–230.
- Hart SM, McNair M, Gamsu MR, Price JF: Pulmonary interstitial emphysema in very low birth weight infants. Arch Dis Child 1983;58:612–616.
- Ratner I, Whitfield J: Acquired subglottic stenosis in the very-low-birth-weight infant. Am J Dis Child 1983;137:40–43.
- Meneses J, Bhandari V, Alves JG, Herrmann D: Noninvasive ventilation for respiratory distress syndrome: a randomized controlled trial. Pediatrics 2011;127:300–307.
- Owen LS, Morley CJ, Davis PG: Neonatal nasal intermittent positive pressure ventilation: a survey of practice in England. Arch Dis Child Fetal Neonatal Ed 2008;93:148–150.
- Barrington KJ, Bull D, Finer NN: Randomized trial of nasal synchronized intermittent mandatory ventilation compared with continuous positive airway pressure after extubation of very low birth weight infants. Pediatrics 2001;107:638–641.
- De Paoli AG, Davis PG, Lemyre B: Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation for preterm neonates: a systematic review and meta-analysis. Acta Paediatr 2003;92:70–75.
- Lin CH, Wang ST, Lin YJ, Yeh TF: Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. Pediatr Pulmonol 1998;26:349–353.
- Carlo WA: Should nasal high-frequency ventilation be used in preterm infants? Acta Paediatr 2008;97:1484–1485.
- Imai Y, Slutsky AS: High frequency oscillatory ventilation and ventilator-induced lung injury. Crit Care Med 2005;33 (3 suppl):S129–134.
- Van Der Hoeven M, Brouwer E, Blanco CE: Nasal high frequency ventilation in neonates with moderate respiratory insufficiency. Arch Dis Child Fetal Neonatal Ed 1998;79:61–63.
- Colaizy TT, Younis UMM, Bell EF, Klein JM: Nasal high-frequency ventilation for premature infants. Acta Paediatr 2008;97:1518–1522.
- De La Roque ED, Bertrand C, Tandonnet O, Rebola M, Roquand E, Renesme L, Elleau C: Nasal high frequency percussive ventilation versus nasal continuous positive airway pressure in transient tachypnea of the newborn. Pediatr Pulmonol 2011;46:218–222.
- Donn SM, Sinha SK: Can mechanical ventilation strategies reduce chronic lung disease? Semin Neonatol 2003;8:441–448.
- Ramanathan R: Optimal ventilator strategies and surfactant to protect the preterm lungs. Neonatology 2008;93:302–308.
- De Luca D, Carnielli VP, Conti G, Piastra M: Noninvasive high frequency oscillatory ventilation through nasal prongs: bench evaluation of efficacy and mechanics. Intens Care Med 2010;36:2094–2100.
- Chang HK: Mechanisms of gas transport during ventilation by high frequency oscillation. J Appl Physiol Respir Environ. Exercise Physiol 1984;56:553–563.
- Ventre KM, Arnold JH: High frequency oscillatory ventilation in acute respiratory failure. Paediatr Respir Rev 2004;5:323–332.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.